|
US4186745A
(en)
|
1976-07-30 |
1980-02-05 |
Kauzlarich James J |
Porous catheters
|
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
|
US4373071A
(en)
|
1981-04-30 |
1983-02-08 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
|
SE8205892D0
(sv)
|
1982-10-18 |
1982-10-18 |
Bror Morein |
Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
|
US5916588A
(en)
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US5036006A
(en)
|
1984-11-13 |
1991-07-30 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
JP2528107B2
(ja)
|
1985-03-15 |
1996-08-28 |
サマ−トン，ジエ−ムス |
ポリヌクレオチド測定試薬と方法
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5153319A
(en)
|
1986-03-31 |
1992-10-06 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4853228A
(en)
|
1987-07-28 |
1989-08-01 |
Micro-Pak, Inc. |
Method of manufacturing unilamellar lipid vesicles
|
|
JPH0731857B2
(ja)
|
1988-02-19 |
1995-04-10 |
三洋電機株式会社 |
磁気記録再生装置におけるリール台駆動装置
|
|
AU627226B2
(en)
|
1988-08-25 |
1992-08-20 |
Liposome Company, Inc., The |
Influenza vaccine and novel adjuvants
|
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
|
FR2645020B1
(fr)
|
1989-03-28 |
1994-06-10 |
Vila Jorge |
Medicament pour le traitement des maladies infectieuses dues aux retrovirus ainsi que pour le traitement des tumeurs
|
|
WO1990014837A1
(en)
|
1989-05-25 |
1990-12-13 |
Chiron Corporation |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5674192A
(en)
|
1990-12-28 |
1997-10-07 |
Boston Scientific Corporation |
Drug delivery
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
FR2676072B1
(fr)
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
US6054288A
(en)
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
|
NZ245015A
(en)
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
|
US5750390A
(en)
|
1992-08-26 |
1998-05-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
|
|
US5693535A
(en)
|
1992-05-14 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
HIV targeted ribozymes
|
|
US5340740A
(en)
|
1992-05-15 |
1994-08-23 |
North Carolina State University |
Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
|
|
EP0646178A1
(en)
|
1992-06-04 |
1995-04-05 |
The Regents Of The University Of California |
expression cassette with regularoty regions functional in the mammmlian host
|
|
JPH07509133A
(ja)
|
1992-07-17 |
1995-10-12 |
リボザイム・ファーマシューティカルズ・インコーポレイテッド |
動物疾患の処置のための方法および剤
|
|
US5474914A
(en)
|
1992-07-29 |
1995-12-12 |
Chiron Corporation |
Method of producing secreted CMV glycoprotein H
|
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
|
US20020102273A1
(en)
|
1995-08-08 |
2002-08-01 |
Robert B. Grieve |
Use of alphavirus expression vectors to produce parasite anitgens
|
|
KR100310510B1
(ko)
|
1993-03-23 |
2002-07-04 |
장 스테판느 |
3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
|
|
JPH09500013A
(ja)
|
1993-06-01 |
1997-01-07 |
ライフ・テクノロジーズ・インコーポレイテッド |
カチオン性脂質による遺伝子免疫
|
|
DK0708772T3
(da)
|
1993-07-15 |
2000-09-18 |
Minnesota Mining & Mfg |
Imidazo[4,5,-c]pyridin-4-aminer
|
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
US5397307A
(en)
|
1993-12-07 |
1995-03-14 |
Schneider (Usa) Inc. |
Drug delivery PTCA catheter and method for drug delivery
|
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
|
JP3403233B2
(ja)
|
1994-01-20 |
2003-05-06 |
テルモ株式会社 |
バルーンカテーテル
|
|
AU2215995A
(en)
|
1994-04-07 |
1995-10-30 |
Akzo Nobel N.V. |
Freeze-dried compositions comprising rna
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US5993850A
(en)
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
FR2726003B1
(fr)
|
1994-10-21 |
2002-10-18 |
Agronomique Inst Nat Rech |
Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
|
|
DE69536153D1
(de)
|
1994-11-17 |
2011-05-05 |
Ich Productions Ltd |
Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
|
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US6071890A
(en)
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
|
US5965434A
(en)
|
1994-12-29 |
1999-10-12 |
Wolff; Jon A. |
Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
|
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
|
US5700642A
(en)
|
1995-05-22 |
1997-12-23 |
Sri International |
Oligonucleotide sizing using immobilized cleavable primers
|
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US6264957B1
(en)
|
1995-09-27 |
2001-07-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Product of infectious respiratory syncytial virus from cloned nucleotide sequences
|
|
CA2244110A1
(en)
*
|
1996-02-12 |
1997-08-14 |
Cobra Therapeutics Limited |
Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
|
|
DE19605548A1
(de)
|
1996-02-15 |
1997-09-04 |
Boehringer Ingelheim Int |
Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
|
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
JP2001503735A
(ja)
|
1996-07-03 |
2001-03-21 |
ユニバーシティ オブ ピッツバーグ |
親水性活性試薬のためのエマルジョン処方物
|
|
WO1998001148A1
(en)
|
1996-07-09 |
1998-01-15 |
President And Fellows Of Harvard College |
Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein
|
|
EP0938298B1
(en)
|
1996-09-13 |
2002-12-04 |
Lipoxen Technologies Limited |
Liposome-based composition
|
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
|
AU753688B2
(en)
|
1997-03-10 |
2002-10-24 |
Ottawa Civic Loeb Research Institute |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
|
CA2289702C
(en)
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
|
US6048546A
(en)
|
1997-07-31 |
2000-04-11 |
Sandia Corporation |
Immobilized lipid-bilayer materials
|
|
US6060308A
(en)
|
1997-09-04 |
2000-05-09 |
Connaught Laboratories Limited |
RNA respiratory syncytial virus vaccines
|
|
US6090619A
(en)
|
1997-09-08 |
2000-07-18 |
University Of Florida |
Materials and methods for intracellular delivery of biologically active molecules
|
|
US6129705A
(en)
|
1997-10-01 |
2000-10-10 |
Medtronic Ave, Inc. |
Drug delivery and gene therapy delivery system
|
|
GB9725084D0
(en)
|
1997-11-28 |
1998-01-28 |
Medeva Europ Ltd |
Vaccine compositions
|
|
US6009406A
(en)
|
1997-12-05 |
1999-12-28 |
Square D Company |
Methodology and computer-based tools for re-engineering a custom-engineered product line
|
|
GB9726555D0
(en)
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Vaccine
|
|
BR9909915A
(pt)
|
1998-04-09 |
2000-12-26 |
Smithkline Beecham Biolog |
Composições adjuvantes
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
|
US6517842B1
(en)
|
1998-06-29 |
2003-02-11 |
The United States Of America As Represented By The Secretary Of The Army |
Marburg virus vaccines
|
|
ATE237312T1
(de)
|
1998-07-20 |
2003-05-15 |
Protiva Biotherapeutics Inc |
In liposomen verkapselte nukleinsäurekomplexe
|
|
GB9817052D0
(en)
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
|
ES2284287T3
(es)
|
1998-10-16 |
2007-11-01 |
Glaxosmithkline Biologicals S.A. |
Sistemas adyuvantes y vacunas.
|
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
ATE492644T1
(de)
|
1999-09-09 |
2011-01-15 |
Curevac Gmbh |
Transfer von mrna unter verwendung von polykationischen verbindungen
|
|
HK1049106A1
(zh)
|
1999-09-24 |
2003-05-02 |
Smithkline Beecham Biologicals S.A. |
聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
|
|
IL148671A0
(en)
|
1999-09-24 |
2002-09-12 |
Smithkline Beecham Biolog |
Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
|
|
DE60038622D1
(de)
|
1999-10-20 |
2008-05-29 |
Univ Johns Hopkins Med |
Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
|
|
US8541008B2
(en)
|
1999-11-19 |
2013-09-24 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Pharmaceutical compositions and methods to vaccinate against candidiasis
|
|
US20010044416A1
(en)
|
2000-01-20 |
2001-11-22 |
Mccluskie Michael J. |
Immunostimulatory nucleic acids for inducing a Th2 immune response
|
|
US20030212022A1
(en)
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
|
WO2001079253A1
(en)
|
2000-04-18 |
2001-10-25 |
Human Genome Sciences, Inc. |
Extracellular matrix polynucleotides, polypeptides, and antibodies
|
|
CN1981873A
(zh)
|
2000-06-09 |
2007-06-20 |
莱古伦公司 |
制备微胶粒的方法和所述微胶粒的用途
|
|
ATE440861T1
(de)
|
2000-07-03 |
2009-09-15 |
Novartis Vaccines & Diagnostic |
Immunisierung gegen chlamydia pneumoniae
|
|
WO2002009645A2
(en)
|
2000-08-01 |
2002-02-07 |
The Johns Hopkins University |
Intercellular transport protein linked to an antigen as a molecular vaccine
|
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
|
EP2292632A3
(en)
|
2000-09-26 |
2012-07-25 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
|
|
US20030138453A1
(en)
|
2000-09-28 |
2003-07-24 |
O'hagan Derek |
Microparticles for delivery of heterologous nucleic acids
|
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
|
WO2002079239A2
(en)
|
2001-01-31 |
2002-10-10 |
U.S. Army Medical Research Institute Of Infectious Diseases |
Chimeric filovirus glycoprotein
|
|
WO2002061113A2
(en)
|
2001-02-01 |
2002-08-08 |
The Johns Hopkins University |
Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
|
|
US20030040498A1
(en)
|
2001-03-14 |
2003-02-27 |
Ansardi David Calvert |
Oncolytic RNA replicons
|
|
JP2004535388A
(ja)
|
2001-04-30 |
2004-11-25 |
ターゲティッド ジェネティクス コーポレイション |
脂質含有薬物送達複合体およびそれらの生成方法
|
|
US20030077251A1
(en)
|
2001-05-23 |
2003-04-24 |
Nicolas Escriou |
Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
|
|
ATE291925T1
(de)
|
2001-06-05 |
2005-04-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
|
|
WO2003018054A1
(en)
|
2001-08-31 |
2003-03-06 |
Chiron Srl. |
Helicobacter pylori vaccination
|
|
WO2003023026A1
(en)
|
2001-09-06 |
2003-03-20 |
Alphavax, Inc. |
Alphavirus replicon vector systems
|
|
EP1425040A2
(en)
|
2001-09-14 |
2004-06-09 |
Cytos Biotechnology AG |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
|
EP1450856B1
(en)
|
2001-09-14 |
2009-11-11 |
Cytos Biotechnology AG |
Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
|
|
WO2003035836A2
(en)
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
FR2832423B1
(fr)
|
2001-11-22 |
2004-10-08 |
Vivalis |
Systeme d'expression de proteines exogenes dans un systeme aviaire
|
|
AU2003211103A1
(en)
|
2002-02-13 |
2003-09-04 |
Northeastern University |
Intracellular delivery of therapeutic agents
|
|
DE10207177A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Fakultativ kationische Lipide
|
|
FR2836924B1
(fr)
|
2002-03-08 |
2005-01-14 |
Vivalis |
Lignees de cellules aviaires utiles pour la production de substances d'interet
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
JP4294584B2
(ja)
|
2002-07-05 |
2009-07-15 |
リポクセン・テクノロジーズ・リミテツド |
核酸ワクチン接種の免疫応答を高めるための方法
|
|
US20060251620A1
(en)
|
2002-08-22 |
2006-11-09 |
Lidia Ivanova |
Inducible alphaviral/orip based gene expression system
|
|
EA008940B1
(ru)
|
2002-09-13 |
2007-10-26 |
Репликор, Инк. |
Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
|
|
AU2003297039B2
(en)
*
|
2002-12-13 |
2009-03-05 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
|
WO2004058166A2
(en)
|
2002-12-23 |
2004-07-15 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
|
CA2511646A1
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Thiosemicarbazones as anti-virals and immunopotentiators
|
|
WO2004064759A2
(en)
|
2003-01-21 |
2004-08-05 |
Chiron Corporation |
Use of tryptanthrin compounds for immune potentiation
|
|
WO2004069148A2
(en)
|
2003-02-04 |
2004-08-19 |
Bar-Ilan University |
Snornai-small nucleolar rna degradation by rna interference in trypanosomatids
|
|
WO2004076645A2
(en)
|
2003-02-27 |
2004-09-10 |
University Of Massachusetts |
Compositions and methods for cytomegalovirus treatment
|
|
EP1608762B1
(en)
*
|
2003-03-20 |
2014-01-08 |
Alphavax, Inc. |
Improved alphavirus replicons and helper constructs
|
|
US20060257852A1
(en)
*
|
2003-04-10 |
2006-11-16 |
Chiron Corporation |
Severe acute respiratory syndrome coronavirus
|
|
DE10319208B4
(de)
|
2003-04-29 |
2005-10-20 |
Grenzebach Bsh Gmbh |
Furniermessermaschine
|
|
US20070042979A1
(en)
|
2003-05-30 |
2007-02-22 |
Junichi Yano |
Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
|
|
WO2005002619A2
(en)
|
2003-06-26 |
2005-01-13 |
Chiron Corporation |
Immunogenic compositions for chlamydia trachomatis
|
|
PT1651666E
(pt)
|
2003-07-11 |
2009-08-28 |
Alphavax Inc |
Vacinas de citomegalovírus à base de alfavírus
|
|
US7368537B2
(en)
|
2003-07-15 |
2008-05-06 |
Id Biomedical Corporation Of Quebec |
Subunit vaccine against respiratory syncytial virus infection
|
|
AU2004257373B2
(en)
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
US7709009B2
(en)
|
2003-07-31 |
2010-05-04 |
Novartis Vaccines And Diagnostics, Srl |
Immunogenic compositions for streptococcus pyogenes
|
|
EP1512393A1
(de)
|
2003-09-08 |
2005-03-09 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
|
|
EP1528101A1
(en)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
WO2005046621A2
(en)
|
2003-11-12 |
2005-05-26 |
The United States Of America As Represented By The Secretary Of The Navy |
Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
|
|
US20120027841A1
(en)
|
2004-01-07 |
2012-02-02 |
Biomedical Research Models, Inc. |
Novel mucosal vaccination approach for herpes simplex virus type-2
|
|
US7303881B2
(en)
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
|
JP5331340B2
(ja)
|
2004-05-18 |
2013-10-30 |
バイカル インコーポレイテッド |
インフルエンザウィルスワクチン組成物、及びその使用方法
|
|
PT1751289E
(pt)
|
2004-05-18 |
2009-03-31 |
Alphavax Inc |
Vectores de alfavirais derivados da tc-83, partículas e métodos
|
|
US20090104226A1
(en)
|
2004-05-21 |
2009-04-23 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus Vectors for Respiratory Pathogen Vaccines
|
|
GB0411428D0
(en)
|
2004-05-21 |
2004-06-23 |
Got A Gene Ab |
Vectors
|
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
AU2005327198B2
(en)
|
2004-07-09 |
2011-03-31 |
University Of North Carolina At Chapel Hill |
Viral adjuvants
|
|
WO2006007712A1
(en)
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
|
EP2149583B1
(en)
|
2004-09-24 |
2015-10-28 |
Novartis AG |
Modified VP1-capsid protein of parvovirus B19
|
|
WO2006038129A2
(en)
|
2004-10-01 |
2006-04-13 |
Novartis Vaccines And Diagnostics Srl |
Hepatitis c virus replication system
|
|
EP1811960A2
(en)
|
2004-11-19 |
2007-08-01 |
Novosom AG |
Improvements in or relating to pharmaceutical compositions for local administration
|
|
GB2421025A
(en)
|
2004-12-09 |
2006-06-14 |
Oxxon Therapeutics Ltd |
HSV vaccination vectors
|
|
CA2597724A1
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド |
尿路病原性菌株由来の抗原
|
|
DE602006008278D1
(de)
|
2005-03-02 |
2009-09-17 |
|
Pharmazeutische zusammensetzung
|
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
AU2006235045A1
(en)
|
2005-03-30 |
2006-10-19 |
J. Craig Venter Institute, Inc. |
Haemophilus influenzae type b
|
|
US7618393B2
(en)
|
2005-05-03 |
2009-11-17 |
Pharmajet, Inc. |
Needle-less injector and method of fluid delivery
|
|
AU2006259858A1
(en)
|
2005-05-12 |
2006-12-28 |
Novartis Vaccines And Diagnostics S.R.L. |
Immunogenic compositions for Chlamydia trachomatis
|
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
|
EP1909758A1
(en)
|
2005-08-02 |
2008-04-16 |
I.D.M. Immuno-Designed Molecules |
Process for the preparation of liposomal formulations
|
|
US7951384B2
(en)
|
2005-08-05 |
2011-05-31 |
University Of Massachusetts |
Virus-like particles as vaccines for paramyxovirus
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
WO2007107304A2
(en)
|
2006-03-17 |
2007-09-27 |
Novosom Ag |
An efficient method for loading amphoteric liposomes with nucleic acid active substances
|
|
EP1764089A1
(en)
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Serum stable liposomes comprising amphoter II lipid mixtures
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
ATE493405T1
(de)
|
2005-09-29 |
2011-01-15 |
Elan Pharm Inc |
Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
|
|
EP1945247A1
(en)
|
2005-10-18 |
2008-07-23 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
|
JP2007112768A
(ja)
|
2005-10-24 |
2007-05-10 |
Kyoto Univ |
肝指向性リポソーム組成物
|
|
EP1954306A2
(en)
|
2005-10-25 |
2008-08-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Compositions comprising yersinia pestis antigens
|
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
|
US9393215B2
(en)
|
2005-12-02 |
2016-07-19 |
Novartis Ag |
Nanoparticles for use in immunogenic compositions
|
|
US7704510B2
(en)
*
|
2006-06-07 |
2010-04-27 |
The Trustees Of Princeton University |
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
PT2035581E
(pt)
|
2006-06-21 |
2012-12-06 |
Scripps Research Inst |
Composição de adn contra o antigénio do estroma tumoral fap e métodos de utilização desta
|
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
EP3207941B3
(en)
|
2006-09-07 |
2020-08-19 |
Scott & White Memorial Hospital |
Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
|
|
US20090022760A1
(en)
|
2006-09-12 |
2009-01-22 |
Alphavax |
Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
WO2008103276A2
(en)
|
2007-02-16 |
2008-08-28 |
Merck & Co., Inc. |
Compositions and methods for potentiated activity of biologicaly active molecules
|
|
US20100196492A1
(en)
|
2007-03-08 |
2010-08-05 |
Green Jordan J |
Electrostatic coating of particles for drug delivery
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
JP5350360B2
(ja)
|
2007-03-29 |
2013-11-27 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
エボラ由来の遺伝子の発現を阻害するための組成物および方法
|
|
US8748591B2
(en)
|
2007-04-17 |
2014-06-10 |
The Board Of Regents Of The University Of Texas System |
Chimeric sindbis-western equine encephalitis virus and uses thereof
|
|
EP3434259A1
(en)
|
2007-05-04 |
2019-01-30 |
Marina Biotech, Inc. |
Amino acid lipids and uses thereof
|
|
EP2152890A1
(en)
|
2007-05-23 |
2010-02-17 |
MannKind Corporation |
Multicistronic vectors and methods for their design
|
|
DE102007029471A1
(de)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
Neue fakultativ kationische Sterole
|
|
DK2947149T3
(en)
|
2007-06-21 |
2018-06-06 |
Alphavax Inc |
ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
|
|
US8202518B2
(en)
|
2007-07-04 |
2012-06-19 |
Ribovax Biotechnologies S.A. |
Antibodies against human cytomegalovirus (HCMV)
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
WO2009026328A2
(en)
|
2007-08-21 |
2009-02-26 |
Immune Disease Institute, Inc. |
Methods of delivery of agents to leukocytes and endothelial cells
|
|
GB0717187D0
(en)
|
2007-09-04 |
2007-10-17 |
Novartis Ag |
Compositions comprising yersinia pestis antigens
|
|
WO2009042794A2
(en)
|
2007-09-26 |
2009-04-02 |
Vanderbilt University |
Venezuelan equine encephalitis replicons expressing paramyxovirus glycoproteins as vaccine
|
|
EP2042193A1
(en)
|
2007-09-28 |
2009-04-01 |
Biomay AG |
RNA Vaccines
|
|
US20090091591A1
(en)
|
2007-10-07 |
2009-04-09 |
Yohanan Sivan |
Printing Systems And Methods For Generating Relief Images
|
|
WO2009079185A2
(en)
|
2007-11-26 |
2009-06-25 |
Novartis Vaccines And Diagnostics, Inc. |
Methods of generating alphavirus particles
|
|
EP2067749A1
(en)
|
2007-11-29 |
2009-06-10 |
Total Petrochemicals France |
Process for purification of an aqueous phase containing polyaromatics
|
|
WO2009074861A2
(en)
|
2007-12-10 |
2009-06-18 |
Powderject Research Limited |
Improved vaccine
|
|
WO2009111088A2
(en)
|
2008-01-02 |
2009-09-11 |
The Johns Hopkins University |
Antitumor immunization by liposomal delivery of vaccine to the spleen
|
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
ITMI20081249A1
(it)
|
2008-07-09 |
2010-01-09 |
Novartis Vaccines & Diagnostic |
Immunogeni di escherichia coli con solubilità migliorata.
|
|
SI2268618T1
(sl)
|
2008-03-03 |
2015-09-30 |
Novartis Ag |
Spojine in sestavki kot modulatorji aktivnosti TLR
|
|
WO2009109860A2
(en)
|
2008-03-06 |
2009-09-11 |
Novartis Ag |
Mutant forms of chlamydia htra
|
|
EP2279254B1
(en)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
|
WO2009132206A1
(en)
|
2008-04-25 |
2009-10-29 |
Liquidia Technologies, Inc. |
Compositions and methods for intracellular delivery and release of cargo
|
|
EP2123758A1
(en)
*
|
2008-05-20 |
2009-11-25 |
Wageningen Universiteit |
Influenza cap-leader sequence
|
|
US20100040650A1
(en)
|
2008-05-30 |
2010-02-18 |
Crowe Jr James E |
Virus-Like paramyxovirus particles and vaccines
|
|
EP2130912A1
(en)
|
2008-06-04 |
2009-12-09 |
Institut für Viruskrankeiten und Immunprophylaxe |
Pestivirus replicons providing an RNA-based viral vector system
|
|
EP2310045A1
(en)
|
2008-06-25 |
2011-04-20 |
Novartis AG |
Rapid responses to delayed booster immunisations
|
|
US20110229969A1
(en)
|
2008-06-25 |
2011-09-22 |
Volker Sandig |
Cell Line for Propagation of Highly Attenuated AlphaViruses
|
|
PE20141398A1
(es)
|
2008-07-16 |
2014-10-18 |
Inst Research In Biomedicine |
Anticuerpos neutralizantes de citomegalovirus humano
|
|
AU2008359583B2
(en)
|
2008-07-16 |
2012-04-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus neutralising antibodies and use thereof
|
|
JP2010025644A
(ja)
|
2008-07-16 |
2010-02-04 |
Kochi Univ Of Technology |
硝酸イオンの呈色試薬並びにこれを用いた硝酸イオンの検出及び定量方法
|
|
WO2010017330A1
(en)
*
|
2008-08-06 |
2010-02-11 |
Novartis Ag |
Microparticles for use in immunogenic compositions
|
|
CL2008002322A1
(es)
|
2008-08-07 |
2009-06-05 |
Univ Concepcion |
Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
|
|
ES2915692T3
(es)
|
2008-08-13 |
2022-06-24 |
California Inst Of Techn |
Nanopartículas portadoras y composiciones, métodos y sistemas relacionados
|
|
US20110177122A1
(en)
|
2008-09-26 |
2011-07-21 |
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services |
Dna prime/activated vaccine boost immunization to influenza virus
|
|
EP2344638A1
(en)
*
|
2008-10-06 |
2011-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of an rna from west nile virus
|
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
WO2010053572A2
(en)
|
2008-11-07 |
2010-05-14 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
EP3699172A3
(en)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
AU2009316680B2
(en)
|
2008-11-18 |
2016-03-24 |
Takeda Vaccines, Inc. |
RSV F VLPs and methods of manufacture and use thereof
|
|
EP2391343B1
(en)
|
2009-01-29 |
2017-03-01 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
|
EP2419129A2
(en)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Compositions for immunising against staphylococcus aerus
|
|
CA2760706C
(en)
|
2009-05-05 |
2019-08-06 |
Alnylam Pharmaceuticals, Inc. |
Methods of delivering oligonucleotides to immune cells
|
|
KR20220038506A
(ko)
|
2009-06-10 |
2022-03-28 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
US20120100207A1
(en)
|
2009-07-02 |
2012-04-26 |
Konica Minolta Holdings, Inc. |
Process for producing liposomes by two-step emulsification method utilizing outer aqueous phase containing specific dispersing agent, process for producing liposome dispersion or dry powder thereof using the process for producing liposomes, and liposome dispersion or dry powder thereof produced thereby
|
|
EP2451475A2
(en)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Self replicating rna molecules and uses thereof
|
|
EP4183412B1
(en)
|
2009-07-15 |
2024-08-14 |
GlaxoSmithKline Biologicals SA |
Rsv f protein compositions and methods for making same
|
|
US8277919B2
(en)
|
2009-07-23 |
2012-10-02 |
VMO Systems, Inc. |
Reflective coating for an optical disc
|
|
EA022786B1
(ru)
|
2009-07-31 |
2016-03-31 |
Этрис Гмбх |
Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
|
|
US9950062B2
(en)
*
|
2009-09-02 |
2018-04-24 |
Glaxosmithkline Biologicals Sa |
Compounds and compositions as TLR activity modulators
|
|
JO3257B1
(ar)
*
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
|
US20110070260A1
(en)
|
2009-09-09 |
2011-03-24 |
Baric Ralph S |
Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
|
|
RU2573409C2
(ru)
|
2009-11-04 |
2016-01-20 |
Дзе Юниверсити Оф Бритиш Коламбиа |
Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
|
|
SI2506857T1
(en)
|
2009-12-01 |
2018-08-31 |
Translate Bio, Inc. |
Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
|
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
ES2769129T3
(es)
|
2009-12-07 |
2020-06-24 |
Univ Pennsylvania |
Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
|
|
US20130017223A1
(en)
|
2009-12-18 |
2013-01-17 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
WO2011076807A2
(en)
|
2009-12-23 |
2011-06-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
EP2525815B1
(en)
*
|
2010-01-24 |
2015-02-25 |
Novartis AG |
Irradiated biodegradable polymer microparticles
|
|
US9744228B2
(en)
*
|
2010-04-07 |
2017-08-29 |
Norvartis Ag |
Method for generating a parvovirus B19 virus-like particle
|
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
|
CA2804591C
(en)
|
2010-07-06 |
2019-01-22 |
Novartis Ag |
Cationic oil-in-water emulsions
|
|
FI4005592T3
(fi)
*
|
2010-07-06 |
2023-01-13 |
|
Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
|
|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
|
CN103153284B
(zh)
|
2010-07-06 |
2015-11-25 |
诺华股份有限公司 |
含有其pKa值有利于RNA递送的脂质的脂质体
|
|
US9770463B2
(en)
*
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
CA2804501C
(en)
*
|
2010-07-06 |
2021-01-26 |
Novartis Ag |
Noro virus derived immunogenic compositions and methods
|
|
US9192661B2
(en)
*
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
US8898852B2
(en)
|
2010-08-04 |
2014-12-02 |
Honeywell International Inc. |
Air burst to clear detection window
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RS63890B1
(sr)
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
JP5911870B2
(ja)
*
|
2010-08-31 |
2016-04-27 |
ノバルティス アーゲー |
免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
|
|
EP3542789A3
(en)
|
2010-08-31 |
2020-01-01 |
GlaxoSmithKline Biologicals SA |
Lipids suitable for liposomal delivery of protein-coding rna
|
|
EP2614072A4
(en)
*
|
2010-09-09 |
2014-03-19 |
Univ Virginia Commonwealth |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR102266691B1
(ko)
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
PH12013500764A1
(en)
|
2010-10-25 |
2015-09-23 |
Stepan Co |
Quaternized fatty amines, amidoamines, and their derivatives from natural oil metathesis
|
|
WO2012092569A2
(en)
|
2010-12-31 |
2012-07-05 |
Selecta Biosciences, Inc. |
Compositions comprising immunostimulatory nucleic acids and related methods
|
|
ES3018416T3
(es)
*
|
2011-01-26 |
2025-05-16 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
|
CA2826199A1
(en)
|
2011-01-31 |
2012-08-09 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
RS56748B1
(sr)
*
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
|
CN103687957A
(zh)
|
2011-05-17 |
2014-03-26 |
现代治疗公司 |
工程化核酸及其用于非人类脊椎动物的方法
|
|
EP4074693A1
(en)
|
2011-06-08 |
2022-10-19 |
Translate Bio, Inc. |
Cleavable lipids
|
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
US11058762B2
(en)
*
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
JP2014522842A
(ja)
*
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
|
RU2014104090A
(ru)
|
2011-07-06 |
2015-08-20 |
Новартис Аг |
Липосомы с эффективным соотношением n:p для доставки молекул phk
|
|
US9655845B2
(en)
*
|
2011-07-06 |
2017-05-23 |
Glaxosmithkline Biologicals, S.A. |
Oil-in-water emulsions that contain nucleic acids
|
|
US9636410B2
(en)
|
2011-07-06 |
2017-05-02 |
Glaxosmithkline Biologicals Sa |
Cationic oil-in-water emulsions
|
|
PT2750707T
(pt)
|
2011-08-31 |
2019-01-23 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para distribuição de arn que codifica imunogénio
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
BR112014008694A2
(pt)
*
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
|
US20140348863A1
(en)
*
|
2011-10-12 |
2014-11-27 |
Alessia Bianchi |
Cmv antigens and uses thereof
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
AU2012358384A1
(en)
|
2011-12-21 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Methods of increasing the viability or longevity of an organ or organ explant
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
AU2014204826A1
(en)
*
|
2013-01-10 |
2015-07-09 |
Seqirus UK Limited |
Influenza virus immunogenic compositions and uses thereof
|
|
US9504747B2
(en)
*
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
CN116549671A
(zh)
|
2016-11-10 |
2023-08-08 |
川斯勒佰尔公司 |
用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
WO2021038508A1
(en)
|
2019-08-30 |
2021-03-04 |
Glaxosmithkline Biologicals Sa |
Jet mixing lipid nanoparticle manufacturing process
|
|
DE102019214469A1
(de)
|
2019-09-23 |
2021-03-25 |
Henkel Ag & Co. Kgaa |
Kit und Verfahren zum Färben von keratinischem Material mit Aminosilikon und farbgebender Verbindung
|
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|